Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?

Journal of Nephrology

Volumn 20, Issue 4, 2007, Pages 410-416

  Diskin, Charles J ^a   Stokes, Thomas J ^a   Dansby, Linda M ^a   Radcliff, Lautrec ^a   Carter, Thomas B ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Angiotensin; Diabetic glomerulosclerosis; Drug therapy; Proteinuria; Renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; LOSARTAN; PENTOXIFYLLINE; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PERMISSIBLE DOSE; MEAN ARTERIAL PRESSURE; PROTEINURIA; TREATMENT DURATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PROTEINURIA; VASODILATOR AGENTS;

EID: 36048950194     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Trachtman H, Zavilowitz B, Bennett B, Goldsmith DI. The effect of captopril on urinary protein excretion in puromycin aminonucleoside nephrosis in rats. Pediatr Res 1985; 19: 828-34.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62.
3. Kloke HJ, Wetzels JF, van Hamersvelt HW, Koene RA, Huysmans FT. Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis. Nephrol Dial Transplant 1993; 8: 808-13.
4. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
6. Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 2006; 21: 683-9.
7. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20.
8. Sengul AM, Altuntas Y, Kurklu A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 2006; 71: 210-9.
9. Chrysotomou A, Pedagogos E, MacGregor L, Becker G. Double blind controlled study on the effect of aldosterone receptor antagonist spironolactone in patients who have persistent protelnuria on ACEI therapy, with an ARB. Clin J Am Soc Nephrol 2006; 1: 256-62.
10. Aminorroaya A, Janghorbani M, Rezvanian H, Aminian T, Gharavi M, Amini M. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus. Nephron Clin Pract 2005; 99: c73-7.
11. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-4.
12. Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006; 69: 1410-5.
13. Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol 2005; 16: 2119-26.
14. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G; the REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-46.
15. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-7.
16. Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P, Crepaldi G. Effect of lercanidipine, compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17: 259-66.
17. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Does the hyperfiltration of minoxidil result in loss of renoprotection conferred by angiotensin inhibition? Kidney Blood Press Res 2006; 29: 54-9.
18. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 2003; 60: 85-9.
19. Tonolo G, Velussi M, Brocco E, Abaterusso C, Carraro A, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Nosadini R. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006; 70: 177-86.
20. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy [review]. Cardiovasc Drugs Ther 1995; 9: 145-9.